Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression
Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression
复制标题
DOI：
10.1200/jco.1998.16.4.1397
复制
发表时间：
1998-04-01
影响因子：
45.3
通讯作者：
Miyake, M
中科院分区：
文献类型：
--
作者：
Adachi, M;Taki, T;Miyake, M
目的：跨膜 4 超家族 (TM4SF) 是最近发现的一个基因家族。据报道，在 TM4SF 成员中，MRP-1/CD9、KAI1/CD82 和 ME491/CD63 可以调节肿瘤进展或转移。在这项研究中，我们研究了非小细胞肺癌 (NSCLC) 患者中 MRP-1、KAI1 和 ME491 这三个基因之间的关系。此外，我们评估了同时评估 NSCLC 中 MRP-1、KAI1 和 ME491 表达的预后价值。 患者和方法：1991 年 1 月至 1994 年 6 月期间，172 名 IIIB 期 NSCLC 患者接受了根治性手术。使用定量逆转录聚合酶链反应 (RT-PCR) 分析，我们研究了这些患者中 MRP-1、KAI1 和 ME491 基因的表达。结果：我们发现 109 名患者（63.4%）患有 MRP-1 阳性肿瘤，42 名患者（24.4%）患有 KAI1 阳性肿瘤。相反，所有 172 名患者均表达 ME491。 MRP-1 表达与 KAI1 表达之间未发现任何关系。我们将这些患者分为三组。将MRP-1和KAI1均阳性的36例患者定义为A组； 79 例 MRP-1 或 KAI1 表达降低的患者被定义为 B 组，其余 57 例 MRP-1 和 KAI1 表达降低的患者被定义为 C 组。这种新的分类与淋巴结状态、肿瘤状态和病理分期相关（分别为 P = .0056、P = .0003 和 P < .0001）。在NSCLC患者中，A组患者的5年生存率显着优于B组患者，远优于C组患者（分别为86.8%、53.9%和31.5%；P < .0001）。 Cox 多变量回归分析显示，NSCLC 中的这种新分类是一个重要的预后因素，淋巴结状态也是如此 (P < .0001)。 结论：我们的结果表明，肺部肿瘤的 MRP-1 和 KAI1 表达低可能与不良预后相关。可以想象，MRP-1和KAI1表达的评估可以识别早期疾病复发风险较高的淋巴结阴性肺癌患者，因此需要强化辅助治疗。 (C) 1998 年美国临床肿瘤学会。
Purpose: The transmembrane-4 superfamily (TM4SF) is a recently discovered family of genes. Of the TM4SF members, MRP-1/CD9, KAI1/CD82, and ME491/CD63 have been reported to modulate tumor progression or metastasis. In this study, we investigated the relationships between these three genes, MRP-1, KAI1, and ME491, in patients with non-small-cell lung cancers (NSCLCs). Moreover, we assessed the prognostic value of evaluating the expressions of MRP-1, KAI1, and ME491 simultaneously in NSCLCs.Patient and Methods: One hundred seventy-two patients up to stage IIIB NSCLC underwent radical surgery during the period of January 1991 through June 1994. Using a quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) analysis, we studied the expression of MRP-1, KAI1, and ME491 genes in these patients.Results: We found that 109 patients (63.4%) had MRP-1-positive tumors and 42 patients (24.4%) had KAI1-positive tumors. Conversely, all 172 patients expressed ME491. No relationship was found between MRP-1 expression and KAI1 expression. We classified these patients into three groups. The 36 patients who were positive for both MRP-1 and KAI1 were defined as group A; the 79 patients with reduced expression of either MRP-1 or KAI1 were defined as group B, and the remaining 57 patients with reduced expression of both MRP-1 and KAI1 were defined as group C. This new classification wets correlated with nodal status, tumor status, and pathologic stage (P = .0056, P = .0003, and P < .0001, respectively). In NSCLC patients, the 5-year survival rate of group A patients was significantly better than that of group B patients and much better than that of group C patients (86.8%, 53.9%, and 31.5%, respectively; P < .0001). Cox multivariate regression analysis showed that this new classification in NSCLCs was a significant prognostic factor, as was the nodal status (P < .0001).Conclusion: Our results suggest that a tow MRP-1 and KAI1 expression by tumors of the lung may be associated with poor prognosis. It is conceivable that the evaluation for MRP-1 and KAI1 expression may identify node-negative lung cancer patients who are at high risk for early disease recurrence, and thus need intensive adjuvant therapy. (C) 1998 by American Society of Clinical Oncology.